MAP2K7 and colorectal cancer: Dabrafenib, a BRAF inhibitor could also be considered in combination with trametinib (MEK inhibitor), as the combination has already been used in BRAF-mutated colorectal cancer patients, particularly when these drugs were first introduced [54].